Table 2.
Somatostatin receptor subtypes mRNA in neuroendocrine tumours.
| Tumor | SSTR1 | SSTR2 | SSTR3 | SSTR4 | SSTR5 |
|---|---|---|---|---|---|
| Gastrinoma | 79%a | 93% | 36% | 61% | 93% |
| Insulinoma | 76% | 81% | 38% | 58% | 57% |
| N-F | 58% | 88% | 42% | 48% | 50% |
| Carcinoid (gut) |
76% | 80% | 43% | 68% | 77% |
SST, somatostatin receptor; N-F, Non functioning;a Indicates the percentage of positive tumours for each sst. mRNA expression may overestimate the number of receptors present, depending on the technique used [PR-polymerase chain reaction, Northern blot, in-situ hybridization].
[Data from Plöckinger U. Biotherapy. Best Practice & Research Clinical Endocrinology & Metabolism 2007; Vol. 21, No. 1, pp. 145-162]